Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
Loughlin AM, Qiao Q, Nunes AP, Öhman P, Ezzy S, Yochum L, Clifford CR, Gately R, Dore DD, Seeger JD. Loughlin AM, et al. Among authors: ohman p. Diabetes Obes Metab. 2018 Apr;20(4):898-909. doi: 10.1111/dom.13175. Epub 2018 Jan 3. Diabetes Obes Metab. 2018. PMID: 29193561 Free PMC article.
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P; DURATION-NEO-2 study investigators. Gadde KM, et al. Among authors: ohman p. Diabetes Obes Metab. 2017 Jul;19(7):979-988. doi: 10.1111/dom.12908. Epub 2017 Mar 17. Diabetes Obes Metab. 2017. PMID: 28205322 Free PMC article. Clinical Trial.
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Jabbour SA, Frías JP, Guja C, Hardy E, Ahmed A, Öhman P. Jabbour SA, et al. Among authors: ohman p. Diabetes Obes Metab. 2018 Jun;20(6):1515-1519. doi: 10.1111/dom.13206. Epub 2018 Feb 4. Diabetes Obes Metab. 2018. PMID: 29316164 Free PMC article. Clinical Trial.
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Frías JP, Hardy E, Ahmed A, Öhman P, Jabbour S, Wang H, Guja C. Frías JP, et al. Among authors: ohman p. Diabetes Obes Metab. 2018 Jun;20(6):1520-1525. doi: 10.1111/dom.13296. Epub 2018 Apr 19. Diabetes Obes Metab. 2018. PMID: 29573139 Free PMC article. Clinical Trial.
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR. Bethel MA, et al. Among authors: ohman p. Diabetes Care. 2020 Feb;43(2):446-452. doi: 10.2337/dc19-1065. Epub 2019 Nov 22. Diabetes Care. 2020. PMID: 31757838 Free PMC article. Clinical Trial.
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
Jabbour SA, Frías JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C. Jabbour SA, et al. Among authors: ohman p. Diabetes Care. 2018 Oct;41(10):2136-2146. doi: 10.2337/dc18-0680. Epub 2018 Aug 6. Diabetes Care. 2018. PMID: 30082326 Free PMC article. Clinical Trial.
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ. Fudim M, et al. Among authors: ohman p. Circulation. 2019 Nov 12;140(20):1613-1622. doi: 10.1161/CIRCULATIONAHA.119.041659. Epub 2019 Sep 23. Circulation. 2019. PMID: 31542942 Free PMC article.
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Frías JP, et al. Among authors: ohman p. Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16. Lancet Diabetes Endocrinol. 2016. PMID: 27651331 Clinical Trial.
49 results